TAmiRNA Senior Scientist Teresa Lara Krammer will attend MEDICA Düsseldorf next week to speak about “thrombomiRs - circulating microRNAs as novel platelet activation markers?”. Reach out to Teresa directly to meet with her before or after her presentation on Tuesday, Nov. 14th at 14:50, Halle1/G37 and discuss our latest developments and how TAmiRNA’s products and services can assist your business!
- Plasma levels of platelet-enriched microRNAs change during antiplatelet therapy in healthy subjectsbiomarkers, diagnose disease, extracellular vesicle, microRNA, platelet-associated miRNAs, smallRNA, thrombomiR, treatment monitoring
We want to draw your attention to our most recent publication where we investigated platelet-enriched miRNAs (thrombomiRs) as suitable candidates for monitoring antiplatelet therapy. The study provides evidence that thrombomiRs are promising biomarker candidates for monitoring the extent of platelet inhibition. This could enable stratification of patients depending on their response to antiplatelet therapy and guide treatment decisions. click here to read the paper
The collaboration between Biogenity and TAmiRNA is a big step towards further enabling our clients to identify new biomarkers that can be used to diagnose disease, monitor treatment response, and predict patient outcomes. And an important step to advance omics research and bring better healthcare to future generations. click here to read the press release